ValuEngine Upgrades Cellect Biotechnology Ltd. (NASDAQ:APOP) to Hold

ValuEngine upgraded shares of Cellect Biotechnology Ltd. (NASDAQ:APOP) from a sell rating to a hold rating in a report issued on Tuesday, August 1st.

Separately, Rodman & Renshaw reissued a buy rating and set a $1.00 price objective (down previously from $10.00) on shares of Cellect Biotechnology in a research report on Tuesday, April 4th.

Cellect Biotechnology (NASDAQ APOP) traded up 7.29% during trading on Tuesday, hitting $7.06. 51,917 shares of the stock traded hands. The company’s 50 day moving average is $7.33 and its 200 day moving average is $7.63. Cellect Biotechnology has a one year low of $2.30 and a one year high of $13.50. The company’s market capitalization is $37.98 million.

ILLEGAL ACTIVITY NOTICE: This story was originally published by BNB Daily and is the sole property of of BNB Daily. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at

About Cellect Biotechnology

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cellect Biotechnology Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology Ltd. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply